Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside (Q38830417)

6 September 2017

1 reference

title

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside (English)

1 reference

6 September 2017

1 reference

Chantal Kuhn

1 reference

6 September 2017

Howard L Weiner

series ordinal

1 reference

6 September 2017

publication date

10 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

889-906

1 reference

Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

An open trial of OKT3 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Murine monoclonal IgG antibodies: Differences in their IgG isotypes can affect the antibody effector activity when using human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Identification of a monoclonal antibody specific for a murine T3 polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

CD3-specific antibodies: a portal to the treatment of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

The importance of regulatory T-cell heterogeneity in maintaining self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Regulatory T cells in nonlymphoid tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

21 January 2018

FOXP3: of mice and men.

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Induced CD4+Foxp3+ regulatory T cells in immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Type 1 regulatory T cells (Tr1) in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Generation and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

TGF-β activation and function in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Tolerogenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Control of TH17 cells occurs in the small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

In vivo instruction of suppressor commitment in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

It takes guts for tolerance: the phenomenon of oral tolerance and the regulation of autoimmune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Induction of immunological tolerance by oral anti-CD3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Immunosuppression and Post-transplant Hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Manipulating regulatory T cells: a promising strategy to treat autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Anti-cytokine therapies in T1D: Concepts and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Molecular engineering and design of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

Metrics for antibody therapeutics development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0049

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0049

1 reference

6 September 2017

1 reference